STOCKHOLM – December 19, 2024. Umecrine Cognition today announced that the company has raised SEK 23,8 million through a convertible loan with attached share options directed to a consortium of…
STOCKHOLM – November 18, 2024. Umecrine Cognition today announces that the company will present late-breaking data from a recent interim analysis of the first part of its ongoing Phase 1b/2a…
STOCKHOLM – October [17], 2024. Umecrine Cognition today announces that the company will attend the 10th Edition of the International Conference on Neurology and Brain Disorders (INBC 2024) to…
STOCKHOLM – July 10, 2024. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 28,3 million according to plan to continue the development of its…
STOCKHOLM – June 28, 2024. Umecrine Cognition today announces that the company has published new nonclinical data in the journal Frontiers in Aging Neuroscience, showing the beneficial effects of…
STOCKHOLM – June 3, 2024. Umecrine Cognition today announces that the company will attend the BIO International Convention in San Diego, USA. The meeting takes place June 3–6th and is expected to…
STOCKHOLM – May 8, 2024. Umecrine Cognition today announces that the first two patients have been randomized into the second part of the company’s ongoing clinical Phase 1b/2 study of…
STOCKHOLM – April 30, 2024. The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 2:00 p.m. on Tuesday 28 May 2024 at…
STOCKHOLM – April 16, 2024. Umecrine Cognition today announces that the company has co-authored a scientific review article with leading experts in the research field on the respective roles of the…
STOCKHOLM – March 22, 2024. Umecrine Cognition today announces the successful completion of the first part (Part A) of its ongoing clinical Phase 1b/2 study in Primary Biliary Cholangitis. Part A…